BYAHConsumer Defensive · Household & Personal Products

BYAH Stock Forecast: Park Ha Biological Technology Co. Ltd. Price Predictions for 2026-2027

Last close, 14 Aug 2026

$3.31

+4.42% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 14 Aug 2026 — in the weakest quartile.

Market cap

$2.5M

Ticker Nerd rank

23 / 100

Median analyst target

—

Analysts covering

—

Total return, dividends reinvested

+5.4%

+2.4%

YTD

−94.8%

−98.6%

From 52W high

−98.6%

From 52W low

+25.4%

$232

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

BYAH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Park Ha Biological Technology Co. Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Aug 2026

23 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Growth

Revisions

Value

Momentum

Quality

Issuance

Volatility

Size (94): Smaller than most of the companies we track.

Volatility (8): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BYAH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BYAH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BYAH appears on the weeks it earns a place.

Estimates

BYAH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Park Ha Biological Technology Co. Ltd. (BYAH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: —
Price / sales: 1.0×
Price / book: 0.4×
EV / EBITDA: 0.7×

Growth & margins

Revenue growth (YoY): 1.5%
Earnings growth (YoY): —
Gross margin: —
Operating margin: −76.5%
Net margin: −214.2%

Returns & dividend

Return on equity: −113.0%
Return on assets: −50.7%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BYAH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHousehold & Personal Products

Company	Market cap	TKN rank
BYAHPark Ha Biological Technology Co. Ltd.	$2.5M	23
TANHTantech Holdings Ltd.	$5.7M	15
RAYRaytech Holding Ltd.	$16.8M	8
UGUnited-Guardian, Inc.	$32.8M	90
DSYBig Tree Cloud Holdings Ltd.	$36.1M	4
BIOTInstinct Bio Technical Co. Holdings, Inc.	$1.6M	34
GROVGrove Collaborative Holdings, Inc.	$43.3M	92

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Park Ha Biological Technology Co. Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BYAH news & analysis

PHH, BYAH Investors Have Opportunity to Lead Park Ha Biological Technology Co., Ltd. Securities Lawsuit

PRNewsWire · 11 Aug 2026negative

Rosen Law Firm reminded investors in Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH, BYAH) of the September 28, 2026 lead plaintiff deadline in a securities lawsuit. The deadline applies to purchasers of the company's securities between December 27, 2024 and July 8, 2025 (the "Class Period").

Why it matters — The announcement indicates Park Ha Biological Technology faces an ongoing securities class-action lawsuit covering a defined class period that BYAH watchers should be aware of.

FAQ

Frequently asked questions about BYAH stock

How does Ticker Nerd's model rank BYAH?

As at 14 Aug 2026, Park Ha Biological Technology Co. Ltd. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

What is the BYAH stock forecast for 2030?

No analyst covering Park Ha Biological Technology Co. Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BYAH are extrapolating price history, which says nothing about the business.

How has BYAH stock performed over the past year?

Park Ha Biological Technology Co. Ltd. returned -98.6% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Park Ha Biological Technology Co. Ltd. do?

Park Ha Biological Technology Co., Ltd. is a consumer products company focused on skincare and cosmetic products under its proprietary Park Ha brand.

What is the latest news on BYAH?

The most recent item we track (PRNewsWire, 11 Aug 2026): "PHH, BYAH Investors Have Opportunity to Lead Park Ha Biological Technology Co., Ltd. Securities Lawsuit". Rosen Law Firm reminded investors in Park Ha Biological Technology Co., Ltd. (NASDAQ: PHH, BYAH) of the September 28, 2026 lead plaintiff deadline in a securities lawsuit. The deadline applies to purchasers of the company's securities between December 27, 2024 and July 8, 2025 (the "Class Period").

Company

About Park Ha Biological Technology Co. Ltd.

Park Ha Biological Technology Co., Ltd. is a consumer products company focused on skincare and cosmetic products under its proprietary Park Ha brand. The company develops and manufactures skincare solutions aimed primarily at addressing problematic skin, including offerings for basic skin protection, exfoliation, sebum film repair, microecological balance at the skin surface, and anti-aging care. Its business is organized around two main segments: Product Sales and Franchise Service, reflecting a model that combines direct product distribution with franchise-based promotion and retail operations. Park Ha Biological Technology Co., Ltd. markets its products through directly operated stores as well as a network of franchisees across China, where its operating subsidiaries also provide in-store beauty services and after-sales skincare support. Founded in 2016 and headquartered in Wuxi, China, the company today occupies a niche within the household and personal care industry, focusing on specialized skincare solutions delivered via a mix of proprietary retail locations and franchise partners.

CEO Ms. Xiaoqiu Zhang · 41 employees · China · https://parkha.cn